Nucana secured nearly $100m in its flotation on Nasdaq, slightly below its target of $115m, though its shares had climbed from an opening price of $15 to $18.37 by the end of the week.
It seems a long time ago that biotech companies dominated headlines with jaw-dropping funding rounds and initial public offerings – a case in point, immunotherapy firm Immunocore, whose roots can be traced back to University of Oxford, smashed European records with a $320m funding round in July 2015.
As for flotations, Cellectis, a gene-editing company backed by French state-owned public investment bank BPIfrance, raised almost double its initial target in a $228m IPO in March 2015, becoming just one of…
